###begin article-title 0
###xml 107 110 107 110 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 18 23 <span type="species:ncbi:9606">human</span>
Overexpression of human mitochondrial valyl tRNA synthetase can partially restore levels of cognate mt-tRNAVal carrying the pathogenic C25U mutation
###end article-title 0
###begin p 1
The authors wish it to be known that, in their opinion, the first two authors should be regarded as joint First Authors
###end p 1
###begin p 2
###xml 0 16 0 16 <!--CREATIVE COMMONS-->
CREATIVE COMMONSThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 2
###begin p 3
###xml 388 389 388 389 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&gt;</bold>
###xml 395 399 395 399 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MTTV</italic>
###xml 640 641 640 641 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&lt;</bold>
###xml 675 678 675 678 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 705 710 705 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 878 881 878 881 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 1067 1070 1067 1070 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 1104 1105 1104 1105 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&gt;</bold>
###xml 1197 1200 1197 1200 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 1321 1326 1321 1326 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 1433 1436 1433 1436 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 1695 1696 1695 1696 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&gt;</bold>
###xml 65 70 <span type="species:ncbi:9606">human</span>
###xml 1243 1248 <span type="species:ncbi:9606">human</span>
###xml 1586 1594 <span type="species:ncbi:9606">patients</span>
Phenotypic diversity associated with pathogenic mutations of the human mitochondrial genome (mtDNA) has often been explained by unequal segregation of the mutated and wild-type genomes (heteroplasmy). However, this simple hypothesis cannot explain the tissue specificity of disorders caused by homoplasmic mtDNA mutations. We have previously associated a homoplasmic point mutation (1624C>T) in MTTV with a profound metabolic disorder that resulted in the neonatal deaths of numerous siblings. Affected tissues harboured a marked biochemical defect in components of the mitochondrial respiratory chain, presumably due to the extremely low (<1%) steady-state levels of mt-tRNAVal. In primary myoblasts and transmitochondrial cybrids established from the proband (index case) and offspring, the marked respiratory deficiency was lost and steady-state levels of the mutated mt-tRNAVal were greater than in the biopsy material, but were still an order of magnitude lower than in control myoblasts. We present evidence that the generalized decrease in steady-state mt-tRNAVal observed in the homoplasmic 1624C>T-cell lines is caused by a rapid degradation of the deacylated form of the abnormal mt-tRNAVal. By both establishing the identity of the human mitochondrial valyl-tRNA synthetase then inducing its overexpression in transmitochondrial cell lines, we have been able to partially restore steady-state levels of the mutated mt-tRNAVal, consistent with an increased stability of the charged mt-tRNA. These data indicate that variations in the levels of VARS2L between tissue types and patients could underlie the difference in clinical presentation between individuals homoplasmic for the 1624C>T mutation.
###end p 3
###begin title 4
INTRODUCTION
###end title 4
###begin p 5
###xml 209 210 209 210 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 211 212 211 212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 829 832 829 832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3 B4 B5">3&#8211;5</xref>
###xml 1111 1114 1111 1114 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6 B7 B8 B9">6&#8211;9</xref>
###xml 58 63 <span type="species:ncbi:9606">human</span>
Diseases due to mtDNA mutation are a significant cause of human morbidity and mortality, but our understanding of the factors that influence the presentation and course of these diseases is far from complete (1,2). In particular, the generally accepted explanation for phenotypic diversity of mtDNA mutations is one of uneven segregation of mutated and wild-type mtDNA to particular tissues, with the resulting phenotype being dependent on this ratio or total amount of wild-type mtDNA in these tissues. This explanation is, however, often inadequate for heteroplasmic mutations and inapplicable to homoplasmic mutations, where the same mtDNA genotype is shared between virtually all molecules in all tissues. Homoplasmic mtDNA mutations had generally been considered as having low pathogenicity, with organ-specific phenotypes (3-5). These mutations show incomplete penetrance and are believed to cause disease in association with unknown environmental or other genetic factors. Exceptions to this rule are the homoplasmic mt-tRNA mutations, which have now been identified in several individuals and families (6-9).
###end p 5
###begin p 6
###xml 70 74 70 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MTTV</italic>
###xml 97 100 97 100 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 107 115 107 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 173 174 173 174 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 785 788 785 788 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 1273 1297 1273 1297 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Saccharomyces cerevisiae</italic>
###xml 1362 1364 1362 1364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 1365 1367 1365 1367 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 1459 1462 1459 1462 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Leu</sup>
###xml 1635 1637 1635 1637 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 1640 1649 1640 1649 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 1.</label>
###xml 1679 1682 1679 1682 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 1813 1814 1813 1814 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1854 1858 1854 1858 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MTTV</italic>
###xml 2182 2184 2182 2184 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 2185 2187 2185 2187 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 2191 2192 2191 2192 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 2197 2198 2197 2198 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 2551 2554 2551 2554 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 2564 2567 2564 2567 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Phe</sup>
###xml 2601 2609 2601 2609 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Leu(UUR)</sup>
###xml 1649 3022 1649 3022 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="7">Steady-state levels of mt-tRNA<sup>Val</sup> are decreased in primary cell lines from the patient and proband but do not show the dramatically low levels evident in tissues. (<bold>A</bold>) Schematic representation of the human <italic>MTTV</italic> gene sequence, highlighting the 1624C&gt;T mutation, corresponding to C25U substitution in the tRNA (<ext-link ext-link-type="uri" xlink:href="http://mamit-trna.u-strasbg.fr">http://mamit-trna.u-strasbg.fr</ext-link>.) This mutation occurs in the D-stem of the tRNA secondary structure that is predicted to weaken the interaction with G10, a base pairing that has previously been shown to modulate interaction with class I-type synthetases (<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B28">28</xref>). (<bold>B</bold> and <bold>C</bold>) High-resolution northern blots were performed on RNA isolated from muscle homogenate (B) or myoblasts (C) of the proband (II-1), offspring (III-10) and two unaffected independent controls C1 and C2 from which myoblast cultures were. Differences in specific activity of the various probes are normalized by calculating ratios of signals for the mt-tRNA<sup>Val</sup> and -tRNA<sup>Phe</sup> species (B, upper panel) or &#8211;tRNA<sup>Leu(UUR)</sup> (B, lower panel; C) in each sample and comparing these ratios between samples on the same blot. Ratios of mt-tRNA levels in homogenate and myoblast sample are compared to C2 (B) or C1 (C) that is set to 100% and are reported under each lane. Representative experiments are shown. RNA was isolated from cell lines on at least five separate occasions over a 2-year period. Variance in ratios did not differ by &gt;2%.</p>
###xml 1649 3022 1649 3022 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="7">Steady-state levels of mt-tRNA<sup>Val</sup> are decreased in primary cell lines from the patient and proband but do not show the dramatically low levels evident in tissues. (<bold>A</bold>) Schematic representation of the human <italic>MTTV</italic> gene sequence, highlighting the 1624C&gt;T mutation, corresponding to C25U substitution in the tRNA (<ext-link ext-link-type="uri" xlink:href="http://mamit-trna.u-strasbg.fr">http://mamit-trna.u-strasbg.fr</ext-link>.) This mutation occurs in the D-stem of the tRNA secondary structure that is predicted to weaken the interaction with G10, a base pairing that has previously been shown to modulate interaction with class I-type synthetases (<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B28">28</xref>). (<bold>B</bold> and <bold>C</bold>) High-resolution northern blots were performed on RNA isolated from muscle homogenate (B) or myoblasts (C) of the proband (II-1), offspring (III-10) and two unaffected independent controls C1 and C2 from which myoblast cultures were. Differences in specific activity of the various probes are normalized by calculating ratios of signals for the mt-tRNA<sup>Val</sup> and -tRNA<sup>Phe</sup> species (B, upper panel) or &#8211;tRNA<sup>Leu(UUR)</sup> (B, lower panel; C) in each sample and comparing these ratios between samples on the same blot. Ratios of mt-tRNA levels in homogenate and myoblast sample are compared to C2 (B) or C1 (C) that is set to 100% and are reported under each lane. Representative experiments are shown. RNA was isolated from cell lines on at least five separate occasions over a 2-year period. Variance in ratios did not differ by &gt;2%.</p></caption>
###xml 3022 3022 3022 3022 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn147f1"/>
###xml 1640 3022 1640 3022 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F1" position="float"><label>Figure 1.</label><caption><p textid="7">Steady-state levels of mt-tRNA<sup>Val</sup> are decreased in primary cell lines from the patient and proband but do not show the dramatically low levels evident in tissues. (<bold>A</bold>) Schematic representation of the human <italic>MTTV</italic> gene sequence, highlighting the 1624C&gt;T mutation, corresponding to C25U substitution in the tRNA (<ext-link ext-link-type="uri" xlink:href="http://mamit-trna.u-strasbg.fr">http://mamit-trna.u-strasbg.fr</ext-link>.) This mutation occurs in the D-stem of the tRNA secondary structure that is predicted to weaken the interaction with G10, a base pairing that has previously been shown to modulate interaction with class I-type synthetases (<xref ref-type="bibr" rid="B27">27</xref>,<xref ref-type="bibr" rid="B28">28</xref>). (<bold>B</bold> and <bold>C</bold>) High-resolution northern blots were performed on RNA isolated from muscle homogenate (B) or myoblasts (C) of the proband (II-1), offspring (III-10) and two unaffected independent controls C1 and C2 from which myoblast cultures were. Differences in specific activity of the various probes are normalized by calculating ratios of signals for the mt-tRNA<sup>Val</sup> and -tRNA<sup>Phe</sup> species (B, upper panel) or &#8211;tRNA<sup>Leu(UUR)</sup> (B, lower panel; C) in each sample and comparing these ratios between samples on the same blot. Ratios of mt-tRNA levels in homogenate and myoblast sample are compared to C2 (B) or C1 (C) that is set to 100% and are reported under each lane. Representative experiments are shown. RNA was isolated from cell lines on at least five separate occasions over a 2-year period. Variance in ratios did not differ by &gt;2%.</p></caption><graphic xlink:href="gkn147f1"/></fig>
###xml 422 427 <span type="species:ncbi:9606">child</span>
###xml 573 579 <span type="species:ncbi:9606">infant</span>
###xml 667 673 <span type="species:ncbi:9606">infant</span>
###xml 1267 1272 <span type="species:ncbi:4932">yeast</span>
###xml 1273 1297 <span type="species:ncbi:4932">Saccharomyces cerevisiae</span>
###xml 1728 1735 <span type="species:ncbi:9606">patient</span>
###xml 1848 1853 <span type="species:ncbi:9606">human</span>
We have previously described a family in whom the homoplasmic 1624C>T MTTV (equivalent to mt-tRNAVal C25U; Figure 1A) mutation underlies a devastating multi-system disease (8). Briefly, the proband in this family (II-1) has histochemical, biochemical and molecular biological evidence of mitochondrial disease but has only mild disease with muscle weakness, fatigue and recurrent migraines. She has one surviving affected child (with Leigh's Disease) from 10 pregnancies by four different unrelated partners. Following her most recent pregnancy, she gave birth to a female infant (III-10) who died in the neonatal period from cardiomyopathy and lactic acidosis. This infant had the same pathological findings in muscle as her mother and the extremely low steady-state levels of mt-tRNAVal in cardiac and skeletal muscle confirmed that the 1624C>T mutation was pathogenic. This mutation, although homoplasmic in all maternally related family members, is clearly neither of 'low pathogenicity' nor is it organ specific, but probably is dependent on polygenic factors for its phenotypic expression. One candidate for such a factor is the cognate aminoacyl synthetase. Elegant studies have shown that the phenotypic effects of various pathogenic mt-tRNA mutations in the yeast Saccharomyces cerevisiae can be suppressed by over-expression of the cognate synthetase (10,11). Indeed, the respiratory-deficient phenotype caused by three separate mutations in mt-tRNALeu were all suppressed by over-expression of leucyl-tRNA synthetase, with different degrees of severity requiring different levels of expression for respiratory compensation (11). Figure 1.Steady-state levels of mt-tRNAVal are decreased in primary cell lines from the patient and proband but do not show the dramatically low levels evident in tissues. (A) Schematic representation of the human MTTV gene sequence, highlighting the 1624C>T mutation, corresponding to C25U substitution in the tRNA (.) This mutation occurs in the D-stem of the tRNA secondary structure that is predicted to weaken the interaction with G10, a base pairing that has previously been shown to modulate interaction with class I-type synthetases (27,28). (B and C) High-resolution northern blots were performed on RNA isolated from muscle homogenate (B) or myoblasts (C) of the proband (II-1), offspring (III-10) and two unaffected independent controls C1 and C2 from which myoblast cultures were. Differences in specific activity of the various probes are normalized by calculating ratios of signals for the mt-tRNAVal and -tRNAPhe species (B, upper panel) or -tRNALeu(UUR) (B, lower panel; C) in each sample and comparing these ratios between samples on the same blot. Ratios of mt-tRNA levels in homogenate and myoblast sample are compared to C2 (B) or C1 (C) that is set to 100% and are reported under each lane. Representative experiments are shown. RNA was isolated from cell lines on at least five separate occasions over a 2-year period. Variance in ratios did not differ by >2%.
###end p 6
###begin p 7
###xml 30 33 30 33 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 164 165 164 165 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 205 209 205 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MTTV</italic>
###xml 533 535 533 535 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 536 538 536 538 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 542 543 542 543 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 548 549 548 549 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C</bold>
###xml 902 905 902 905 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 915 918 915 918 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Phe</sup>
###xml 952 960 952 960 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Leu(UUR)</sup>
###xml 79 86 <span type="species:ncbi:9606">patient</span>
###xml 199 204 <span type="species:ncbi:9606">human</span>
Steady-state levels of mt-tRNAVal are decreased in primary cell lines from the patient and proband but do not show the dramatically low levels evident in tissues. (A) Schematic representation of the human MTTV gene sequence, highlighting the 1624C>T mutation, corresponding to C25U substitution in the tRNA (.) This mutation occurs in the D-stem of the tRNA secondary structure that is predicted to weaken the interaction with G10, a base pairing that has previously been shown to modulate interaction with class I-type synthetases (27,28). (B and C) High-resolution northern blots were performed on RNA isolated from muscle homogenate (B) or myoblasts (C) of the proband (II-1), offspring (III-10) and two unaffected independent controls C1 and C2 from which myoblast cultures were. Differences in specific activity of the various probes are normalized by calculating ratios of signals for the mt-tRNAVal and -tRNAPhe species (B, upper panel) or -tRNALeu(UUR) (B, lower panel; C) in each sample and comparing these ratios between samples on the same blot. Ratios of mt-tRNA levels in homogenate and myoblast sample are compared to C2 (B) or C1 (C) that is set to 100% and are reported under each lane. Representative experiments are shown. RNA was isolated from cell lines on at least five separate occasions over a 2-year period. Variance in ratios did not differ by >2%.
###end p 7
###begin p 8
###xml 101 106 101 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 229 232 229 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 802 805 790 793 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 1051 1054 1039 1042 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 1109 1115 1097 1103 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VARS2L</italic>
###xml 324 332 <span type="species:ncbi:9606">patients</span>
###xml 615 623 <span type="species:ncbi:9606">patients</span>
###xml 1144 1151 <span type="species:ncbi:9606">patient</span>
###xml 1329 1337 <span type="species:ncbi:9606">patients</span>
Here, we report the establishment of homoplasmic primary myoblasts and fibroblasts plus a variety of transmitochondrial cybrid cell lines all carrying the 1624C>T transition. Although the steady-state level of the mutated mt-tRNAVal was not depleted to the vanishingly low levels measured in mature skeletal muscle from the patients (<1% of control values), decreases of approximately90% were detected when normalized to other mt-tRNA species and compared to controls. This variability was unexpected, but may give an important clue to why the mutation can lead to such variability in clinical presentation between patients. Hence, an investigation into the underlying cause of this variability was undertaken. The decrease was found to be due greatly to the reduced stability of the deacylated mt-tRNAVal C25U. Over-expression of the cognate valyl synthetase, or inhibition of mitochondrial protein synthesis, processes that would be likely to result in the increased aminoacylation of the mutated tRNA, resulted in partial restoration of the mt-tRNAVal levels. We suggest that relative expression levels of VARS2L may underlie the tissue and patient variability of this homoplasmic mt-tRNA disease. Further, as the data show, levels of the aminoacylated form can be artificially modulated, thus a potential method for treating patients with this, or similar, disorders could be considered.
###end p 8
###begin title 9
METHODS
###end title 9
###begin title 10
Tissue culture manipulations
###end title 10
###begin p 11
###xml 43 44 37 38 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 169 180 163 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">post-mortem</italic>
###xml 236 238 230 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 426 427 420 421 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 632 633 625 626 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 865 866 858 859 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 337 341 <span type="species:ncbi:9913">calf</span>
###xml 358 363 <span type="species:ncbi:9031">chick</span>
###xml 671 675 <span type="species:ncbi:9913">calf</span>
All cells were grown at 37degreesC in 5% CO2 under humidified conditions. Primary myoblast and fibroblast cultures were established from muscle or skin biopsy (II-1) or post-mortem biopsy (III-10) using techniques described previously (12). Myoblasts were grown in Hams F10 (Invitrogen Ltd, Paisley UK) supplemented with 20% (v:v) fetal calf serum, 1% (v:v) chick-embryo extract (ICN Flow Biomedicals, High Wycombe, UK), 2 mM l-glutamine, 1 x non-essential amino acids (NEAA), 100 mug/ml streptomycin and 100 U/ml penicillin. Fibroblasts were routinely grown in Eagle's Minimum Essential Medium (EMEM, Sigma) supplemented with 2 mM l-glutamine, 1 x NEAA, 10% (v:v) fetal calf serum with streptomycin and penicillin as described above. In one experiment, fibroblasts were also grown in valine-deficient EMEM (Sigma-Aldrich Co.Ltd, Dorset, UK) supplemented with 4 mM l-valine.
###end p 11
###begin p 12
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trans</italic>
###xml 141 142 141 142 <sc xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">l</sc>
###xml 124 128 <span type="species:ncbi:9913">calf</span>
Transmitochondrial cybrids were grown in Dulbecco's Modified Essential Media (DMEM, Sigma) supplemented with 5% (v:v) fetal calf serum, 2 mM l-glutamine with streptomycin and penicillin. Cells devoid or depleted of mtDNA were further supplemented by 50 mug/ml uridine and 1 mM pyruvate.
###end p 12
###begin title 13
Isolation of RNA and high-resolution northern blot analysis
###end title 13
###begin p 14
###xml 134 135 122 123 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 445 446 433 434 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 586 588 573 575 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 770 778 757 765 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Leu[UUR]</sup>
###xml 787 790 774 777 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Phe</sup>
###xml 802 805 789 792 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 932 940 919 927 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Leu[UUR]</sup>
###xml 1133 1136 1120 1123 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Phe</sup>
###xml 1321 1324 1308 1311 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 1551 1553 1534 1536 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 1945 1946 1910 1911 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">6</sup>
###xml 728 733 <span type="species:ncbi:9606">human</span>
###xml 919 924 <span type="species:ncbi:9606">human</span>
###xml 1120 1125 <span type="species:ncbi:9606">human</span>
###xml 1308 1313 <span type="species:ncbi:9606">human</span>
TRIZOL Reagent (Invitrogen) was used to extract total RNA from approximately200 mg of skeletal and cardiac muscle and from 1 to 2 x 106 cultured myoblasts or fibroblasts. Large RNA species were removed by precipitation with an equal volume of 10 M LiCl permitting subsequent precipitation of smaller RNA molecules (5S and tRNAs) from the resulting supernatant. The precipitated small RNAs were re-suspended in a minimal volume of DEPC-treated dH2O and 1 mug aliquots were then electrophoresed through a 13% (w:v) 8 M urea polyacrylamide gel and transferred all as previously described (12). Separated RNA was electroblotted onto a GeneScreen Plus membrane (PerkinElmer, Beaconsfield, UK) and fixed by UV irradiation. Regions of human mtDNA encoding the genes for mt-tRNALeu[UUR], mt-tRNAPhe and mt-tRNAVal were PCR amplified and purified (QIAquick PCR purification columns, Qiagen) to produce probes for the blots. The human mt-tRNALeu[UUR] probe was generated using the forward primer L3200 (positions 3200-3219) 5'-TATACCCACACCCACCCAAG-3' and reverse primer H3353 (positions 3353-3334) 5'-GCGATTAGAATGGGTACAAT-3'. The human mt-tRNAPhe probe was generated using the forward primer L552 (positions 552-570) 5'-CCAAACCCCAAAGACACCC-3' and reverse primer H712 (positions 712-694) 5'-GAACGGGGATGCTTGCATG-3'. The human mt-tRNAVal probe was generated using the forward primer L1579 (positions 1579-1598) 5'-CTGGAAAGTGCACTTGGACG-3'and reverse primer H1734 (positions 1734-1714) 5'-GGGTAAATGGTTTGGCTAAGG-3'. Purified amplicons were radio-labelled with [alpha-32P] dCTP (3000 Ci/mmol, GE Healthcare) using the random primer method and unincorporated nucleotides removed by gel filtration through a Sephadex G-50 DNA grade column (GE Healthcare, Amersham, UK). Membranes were probed at 42degreesC in hybridization solution [5 x SSPE, 1% SDS, 10% (w:v) dextran sulphate, 50% (v:v) formamide and 5 x Denhardt's solution] for 16 h with approximately 1-2 x 106 c.p.m. of each radiolabelled probe. Membranes were then incubated at 42degreesC for 16 h. Where appropriate, unlabelled amplicon was added to dilute the specific activity of the probe. Post-hybridization, non-specifically bound radiolabelled probe was removed by a series of washes: 2 x 15 min with 2 x SSPE at room temperature, 1 x 15 min with 2 x SSPE/2% (w:v) SDS. Membranes were then placed in PhosphorImage cassettes and subjected to ImageQuant (Molecular Dynamics, GE Healthcare) analysis after a 24 h exposure.
###end p 14
###begin title 15
In vivo mitochondrial protein synthesis
###end title 15
###begin p 16
###xml 365 367 358 360 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
Myoblasts were grown under the same conditions described above on 35 mm plates. Growth medium was removed, the myoblasts rinsed with methionine-free DMEM (Sigma) and placed in methionine-free medium supplemented with 10% (v:v) dialysed FBS (1000 MWCO; Sigma) containing 100 mug/ml emetine hydrochloride (Sigma) and incubated for 6 min at 37degreesC. Radiolabelled [35S] EasyTag methionine/cysteine (500 muCi, approximately1000 Ci/mmol; Perkin Elmer), was then added and the myoblasts incubated for 2 h before washing, re-suspension in PBS and dissolution in 50% (v:v) sample buffer [0.125 M Tris-HCl pH 6.8, 50% (v:v) glycerol, 10% (w:v) SDS, 0.1% (w:v) bromophenol blue, 5% (v:v) beta-mercaptoethanol]. Samples (20 mug protein) were loaded onto a 4-20% or 10-20% Tris-glycine pre-cast gel (Novex; Invitrogen) and electrophoresed (20 mA) in standard Tris-glycine buffer. Following electrophoresis, the gel was fixed in 3% (v:v) glycerol, 10% (v:v) glacial acetic acid, 30% (v:v) methanol for 1 h, before drying at 60degreesC. The gel was then placed in a PhosphorImage cassette and ImageQuant analysis performed after a 16 h exposure.
###end p 16
###begin title 17
mt-tRNA stability experiments
###end title 17
###begin p 18
###xml 9 10 9 10 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
Six 75 cm2 flasks of primary myoblasts were grown to 75-80% confluency and fed with 20 ml of culture medium 16-24 h prior to the experiment. At time 0, ethidium bromide was added directly to the medium to a final concentration of 250 ng/ml. Cells were harvested at the indicated time points and low molecular weight RNA was extracted. Aliquots of the RNA were then electrophoresed through a 4% (w:v) agarose gel for assessment of quality and relative quantification. Samples were fractionated through a 13% polyacrylamide, 8 M urea gel as described earlier.
###end p 18
###begin title 19
Production and visualization of the VARS2L-GFP fusion protein
###end title 19
###begin p 20
###xml 849 850 847 848 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
A 735-bp amplicon encoding the initiation codon and N-terminal 232 residues of VARS2L flanked by BamH1 restriction sites was generated by PCR with the KOD Hot Start high-fidelity polymerase (Novagen, Merck Biosciences Ltd, Nottingham, UK), using the following primers: 5' CACACAGGATCCTAATGTGCTCT CTCTC 3' and 5'-CTCTCTGGATCCTGCTCACAGATCTCTCC-3' and cDNA clone KIAA1885 (kindly provided by the Kasuza DNA Research Institute, Chiba, Japan) as template. This amplicon was confirmed by DNA sequence analysis and ligated in frame and upstream of GFP in pGFP3 (pcDNA3.1 Invitrogen, containing the GFP open reading frame and multiple cloning site). HeLa cells were seeded onto coverslips and transiently transfected with this fusion construct (5 mug; SuperFect, Qiagen) following the manufacturer's recommendations. After 24 h, 0.4 muM Mitotracker Red CM-H2XRos (Molecular Probes) was added to the growth media for 45 min, prior to washing and fixing in 1% (v:v) paraformaldehyde for 10 min. The coverslips were mounted with Vectashield (H-1200 containing DAPI for nuclear visualization, Vector Laboratories Ltd, Peterborough, UK). Fluorescence was visualized with a Leica (Nussloch, Germany) DMRA. Images were recorded using a cooled CCD camera (Spot-2, Diagnostics Instruments) and imaging system (MetaMorph 4.5, Universal Imaging Corporation, Pennsylvania, USA).
###end p 20
###begin title 21
###xml 36 41 <span type="species:ncbi:9606">human</span>
Over-expression and purification of human VARS2L
###end title 21
###begin p 22
Various GST-fusion constructs were made by producing and cloning the relevant amplicons derived from KIAA1885 template cDNA into SalI-NotI linearized pGEX-6P-1 (GE Healthcare) using the following forward primers:
###end p 22
###begin p 23
Delta64 5'-GCACCAGTCGACGCAAGTCACCTGCAGA AT-3'
###end p 23
###begin p 24
Delta78 5'-GCACCAGTCGACCTACGAAACCCGGTG-3'
###end p 24
###begin p 25
Delta92 5'-GCACCAGTCGACTGCCTCCTGCATACAG C-3'
###end p 25
###begin p 26
Delta102 5'-GCACCAGTCGACGATATGTTGAGGCTG C-3'
###end p 26
###begin p 27
Amplicons were all generated by standard 35-cycle PCR and KOD Hot Start polymerase (Novagen) using the same reverse primer
###end p 27
###begin p 28
###xml 133 149 133 149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Escherichia coli</italic>
###xml 133 149 <span type="species:ncbi:562">Escherichia coli</span>
5'-CACACAGCGGCCGCTCAAAGACAGGTCTGAG-3' and were NotI-SalI digested prior to ligation. The resultant constructs were used to transform Escherichia coli Rosetta(DE3)pLysS and fusion protein was expressed (1 mM IPTG) at 16degreesC overnight. Soluble GST-VARS2L fusion protein was affinity purified using glutathione-Sepharose 4B before release of the VARS2L by PreScission protease (GE Healthcare) following manufacturer's recommendations. Yield of soluble protein differed dependent on truncation size, but specific activities were similar.
###end p 28
###begin title 29
Production of anti-VARS2L antibodies
###end title 29
###begin p 30
###xml 160 166 <span type="species:ncbi:9986">Rabbit</span>
As the cytosolic and predicted mitochondrial valyl synthetase share common sequence elements, the use of full-length VARS2L as antigen could not be considered. Rabbit anti-sera were raised against two synthetic peptides MVRDRQGRKMSKSLG and TARTPSEGEAGTQRQ representing regions of primary sequence unique to the putative mitochondrial protein and affinity purified by Eurogentec, Belgium.
###end p 30
###begin title 31
Production of an mtDNA depleted HEK293 Flip-In T-Rex cell line
###end title 31
###begin p 32
HEK293 Flip-In T-Rex cells (Invitrogen) were seeded into 6-well plates in DMEM supplemented with 10% (w:v) FBS, 50 mug/ml uridine in the presence of 10 mug/ml blasticidin and 100 mug/ml zeocin. Upon reaching 50% confluency, cells were treated with 100 ng/ml ethidium bromide and maintained in growth medium with ethidium bromide for 4-6 weeks.
###end p 32
###begin title 33
Generation of HEK293 Flip-In T-REx transmitochondrial cybrids
###end title 33
###begin p 34
###xml 82 87 82 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 213 215 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 234 235 234 235 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">7</sup>
###xml 365 366 364 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 591 592 584 585 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">g</italic>
###xml 1001 1002 987 988 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3</sup>
###xml 1010 1011 996 997 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4</sup>
###xml 1015 1016 999 1000 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sup>
Cytoplasts for fusion with HEK293 Flip-In T-REx cells were produced from 143B.206 transmitochondrial cybrids homoplasmic for the 1624C>T mutation by centrifugation on a Percoll isopycnic gradient as described by (13). In short, 2 x 107 143B cybrids were re-suspended in 20 ml 1:1 mixture of Percoll:DMEM containing 20 mug/ml cytochalasin B and centrifuged at 44 000g for 70 min at 20degreesC. All cytoplasts were recovered, diluted with 10 vol of DMEM, washed and re-suspended in DMEM. For fusion, cytoplasts were mixed with mtDNA-depleted HEK293 cells in a 1:1 ratio and centrifuged at 1100g for 5 min to form a pellet. DMEM was removed and the cells re-suspended in 0.2 ml of 50% (w:v) polyethylene glycol 1500 (BDH Limited). After 60 s, DMEM (10 ml) was added to the cells that were then gently re-suspended and left to recover at 37degreesC for 45 min. Cells were then plated in DMEM supplemented with 10% (v:v) FBS, 50 mug/ml of uridine and 1 mM Na pyruvate at a variety of cell densities (5 x 103 -2 x 104 rho0/ml). After 24 h, the medium was replaced with DMEM supplemented with 10% dialysed FBS. To select against any non-enucleated 143B donors, cybrids were grown in 100 mug/ml zeocin, 10 mug/ml blasticidin S.
###end p 34
###begin title 35
Production of VARS2L-inducible cell lines
###end title 35
###begin p 36
###xml 74 80 74 80 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VARS2L</italic>
For inducible over-expression, a 3653 bp EcoRV-NotI containing the entire VARS2L open reading frame was generated from the original Kazusa clone (KIAA1885) and inserted into pcDNA5/FRT/TO (Invitrogen). Constructs were isolated from transfectants and confirmed by restriction digest mapping and sequence analysis. Stable and inducible transfectants were generated in HEK293 Flip-In T-REx cells (Invitrogen) following company recommendations and selected for growth in hygromycin B (100 mug/ml). Crucially, the standard calcium phosphate method of transfection was necessary, as the use of other transfection reagents resulted in the loss of the mutated mtDNA for unknown reasons. Individual clones were expanded and inducible expression of VARS2L (48 h; 1 mug/ml tetracycline) confirmed by western analysis.
###end p 36
###begin title 37
RESULTS
###end title 37
###begin title 38
###xml 44 45 44 45 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&gt;</bold>
###xml 75 78 75 78 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
Primary cell lines homoplasmic for the 1624C>T mutation harbour low mt-tRNAVal levels
###end title 38
###begin p 39
###xml 20 23 20 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 167 170 167 170 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Phe</sup>
###xml 172 180 172 180 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 191 199 191 199 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Leu(UUR)</sup>
###xml 201 209 201 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 223 224 223 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B8">8</xref>
###xml 447 455 447 455 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 490 493 490 493 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 27 34 <span type="species:ncbi:9606">patient</span>
###xml 589 597 <span type="species:ncbi:9606">patients</span>
The level of mt-tRNAVal in patient-derived muscle or cardiac tissue homoplasmic for the 1624C>T mutation is vanishingly low (<1% of control) when normalized to mt-tRNAPhe [Figure 1A, or -tRNALeu(UUR) (Figure 1B and C, and (8)], consistent with this mutation contributing to the respiratory defect. Primary cell lines (myoblasts and fibroblasts) were established from the proband (II-1) and from one of her affected offspring (III-10). As shown in Figure 1, the steady-state level of mt-tRNAVal was lower than the comparable control lines, albeit that the dramatic loss demonstrated in the patients' tissue was not recapitulated.
###end p 39
###begin p 40
###xml 204 207 204 207 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 400 407 <span type="species:ncbi:9606">patient</span>
To determine whether this was simply a consequence of the culture conditions, we assessed whether varying the concentration of valine in the culture medium could modulate the steady-state level of mt-tRNAVal in fibroblasts. Susceptibility to limiting valine concentrations (data not shown) or to 10-fold higher valine concentrations than standard (4 mM, Figure S1) did not differ between control and patient fibroblasts.
###end p 40
###begin title 41
###xml 58 59 58 59 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&gt;</bold>
The profound biochemical defects associated with the 1624C>T mutation in tissue are not found in primary cell lines
###end title 41
###begin p 42
###xml 50 53 50 53 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 297 300 297 300 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 552 555 552 555 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 656 659 656 659 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 771 774 771 774 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 884 886 884 886 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">35</sup>
###xml 1136 1139 1136 1139 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 1279 1287 1279 1287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F2">Figure 2</xref>
###xml 1418 1425 1418 1425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">Table 1</xref>
###xml 1610 1613 1610 1613 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 1678 1687 1678 1687 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 2.</label>
###xml 1714 1717 1714 1717 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 1852 1858 1852 1858 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n vivo</italic>
###xml 1942 1944 1942 1944 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 1687 2219 1687 2218 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="43">Decreased levels of mt-tRNA<sup>Val</sup> C25U could not be shown to affect mitochondrial protein synthesis. Myoblasts from patient and control were grown in culture prior to i<italic>n vivo</italic> mitochondrial protein labelling as described in Materials and methods section and (<xref ref-type="bibr" rid="B29">29</xref>). Following inhibition of cytosolic protein synthesis, radiolabelled methionine/cysteine was added for 2 h and whole-cell lysates (20 &#956;g total protein) separated by SDS&#8211;PAGE. A representative PhosphorImage is shown. Attribution of products is determined by reference to 29.</p>
###xml 1687 2219 1687 2218 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="43">Decreased levels of mt-tRNA<sup>Val</sup> C25U could not be shown to affect mitochondrial protein synthesis. Myoblasts from patient and control were grown in culture prior to i<italic>n vivo</italic> mitochondrial protein labelling as described in Materials and methods section and (<xref ref-type="bibr" rid="B29">29</xref>). Following inhibition of cytosolic protein synthesis, radiolabelled methionine/cysteine was added for 2 h and whole-cell lysates (20 &#956;g total protein) separated by SDS&#8211;PAGE. A representative PhosphorImage is shown. Attribution of products is determined by reference to 29.</p></caption>
###xml 2219 2219 2218 2218 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn147f2"/>
###xml 1678 2219 1678 2218 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F2" position="float"><label>Figure 2.</label><caption><p textid="43">Decreased levels of mt-tRNA<sup>Val</sup> C25U could not be shown to affect mitochondrial protein synthesis. Myoblasts from patient and control were grown in culture prior to i<italic>n vivo</italic> mitochondrial protein labelling as described in Materials and methods section and (<xref ref-type="bibr" rid="B29">29</xref>). Following inhibition of cytosolic protein synthesis, radiolabelled methionine/cysteine was added for 2 h and whole-cell lysates (20 &#956;g total protein) separated by SDS&#8211;PAGE. A representative PhosphorImage is shown. Attribution of products is determined by reference to 29.</p></caption><graphic xlink:href="gkn147f2"/></fig>
###xml 2219 2227 2218 2226 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 1.</label>
###xml 2227 2341 2226 2340 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="44">Biochemical analysis of mitochondrial enzymes from tissue homogenates and myoblasts of patient and control samples</p>
###xml 2227 2341 2226 2340 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="44">Biochemical analysis of mitochondrial enzymes from tissue homogenates and myoblasts of patient and control samples</p></caption>
###xml 2341 2347 2340 2346 <th xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Sample</th>
###xml 2347 2359 2346 2358 <th xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Complex I/CS</th>
###xml 2359 2372 2358 2371 <th xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Complex II/CS</th>
###xml 2372 2385 2371 2384 <th xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Complex IV/CS</th>
###xml 2341 2385 2340 2384 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><th rowspan="1" colspan="1">Sample</th><th rowspan="1" colspan="1">Complex I/CS</th><th rowspan="1" colspan="1">Complex II/CS</th><th rowspan="1" colspan="1">Complex IV/CS</th></tr>
###xml 2341 2385 2340 2384 <thead xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" align="left"><tr><th rowspan="1" colspan="1">Sample</th><th rowspan="1" colspan="1">Complex I/CS</th><th rowspan="1" colspan="1">Complex II/CS</th><th rowspan="1" colspan="1">Complex IV/CS</th></tr></thead>
###xml 2385 2402 2384 2401 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Muscle homogenate</td>
###xml 2402 2402 2401 2401 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"/>
###xml 2402 2402 2401 2401 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"/>
###xml 2402 2402 2401 2401 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"/>
###xml 2385 2402 2384 2401 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1">Muscle homogenate</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr>
###xml 2411 2412 2410 2411 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 2402 2418 2401 2417 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Control (<italic>n</italic> = 15)</td>
###xml 2418 2433 2417 2430 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.240 &#177; 0.060</td>
###xml 2433 2448 2430 2443 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.320 &#177; 0.088</td>
###xml 2448 2463 2443 2456 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">1.340 &#177; 0.390</td>
###xml 2402 2463 2401 2456 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1">Control (<italic>n</italic> = 15)</td><td rowspan="1" colspan="1">0.240 &#177; 0.060</td><td rowspan="1" colspan="1">0.320 &#177; 0.088</td><td rowspan="1" colspan="1">1.340 &#177; 0.390</td></tr>
###xml 2463 2475 2456 2468 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Patient II-1</td>
###xml 2475 2480 2468 2473 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.053</td>
###xml 2480 2485 2473 2478 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.251</td>
###xml 2485 2490 2478 2483 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.520</td>
###xml 2463 2490 2456 2483 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1">Patient II-1</td><td rowspan="1" colspan="1">0.053</td><td rowspan="1" colspan="1">0.251</td><td rowspan="1" colspan="1">0.520</td></tr>
###xml 2490 2504 2483 2497 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Patient III-10</td>
###xml 2504 2509 2497 2502 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.023</td>
###xml 2509 2514 2502 2507 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.327</td>
###xml 2514 2519 2507 2512 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.244</td>
###xml 2490 2519 2483 2512 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1">Patient III-10</td><td rowspan="1" colspan="1">0.023</td><td rowspan="1" colspan="1">0.327</td><td rowspan="1" colspan="1">0.244</td></tr>
###xml 2519 2528 2512 2521 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Myoblasts</td>
###xml 2528 2528 2521 2521 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"/>
###xml 2528 2528 2521 2521 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"/>
###xml 2528 2528 2521 2521 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1"/>
###xml 2519 2528 2512 2521 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1">Myoblasts</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr>
###xml 2537 2538 2530 2531 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 2528 2543 2521 2536 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Control (<italic>n</italic> = 3)</td>
###xml 2543 2558 2536 2549 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.129 &#177; 0.038</td>
###xml 2558 2573 2549 2562 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.262 &#177; 0.067</td>
###xml 2573 2588 2562 2575 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.783 &#177; 0.187</td>
###xml 2528 2588 2521 2575 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1">Control (<italic>n</italic> = 3)</td><td rowspan="1" colspan="1">0.129 &#177; 0.038</td><td rowspan="1" colspan="1">0.262 &#177; 0.067</td><td rowspan="1" colspan="1">0.783 &#177; 0.187</td></tr>
###xml 2588 2602 2575 2589 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">Patient III-10</td>
###xml 2602 2607 2589 2594 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.089</td>
###xml 2607 2612 2594 2599 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.185</td>
###xml 2612 2617 2599 2604 <td xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" rowspan="1" colspan="1">0.295</td>
###xml 2588 2617 2575 2604 <tr xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><td rowspan="1" colspan="1">Patient III-10</td><td rowspan="1" colspan="1">0.089</td><td rowspan="1" colspan="1">0.185</td><td rowspan="1" colspan="1">0.295</td></tr>
###xml 2385 2617 2384 2604 <tbody xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" align="left"><tr><td rowspan="1" colspan="1">Muscle homogenate</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Control (<italic>n</italic> = 15)</td><td rowspan="1" colspan="1">0.240 &#177; 0.060</td><td rowspan="1" colspan="1">0.320 &#177; 0.088</td><td rowspan="1" colspan="1">1.340 &#177; 0.390</td></tr><tr><td rowspan="1" colspan="1">Patient II-1</td><td rowspan="1" colspan="1">0.053</td><td rowspan="1" colspan="1">0.251</td><td rowspan="1" colspan="1">0.520</td></tr><tr><td rowspan="1" colspan="1">Patient III-10</td><td rowspan="1" colspan="1">0.023</td><td rowspan="1" colspan="1">0.327</td><td rowspan="1" colspan="1">0.244</td></tr><tr><td rowspan="1" colspan="1">Myoblasts</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Control (<italic>n</italic> = 3)</td><td rowspan="1" colspan="1">0.129 &#177; 0.038</td><td rowspan="1" colspan="1">0.262 &#177; 0.067</td><td rowspan="1" colspan="1">0.783 &#177; 0.187</td></tr><tr><td rowspan="1" colspan="1">Patient III-10</td><td rowspan="1" colspan="1">0.089</td><td rowspan="1" colspan="1">0.185</td><td rowspan="1" colspan="1">0.295</td></tr></tbody>
###xml 2341 2617 2340 2604 <table xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" frame="hsides" rules="groups"><thead align="left"><tr><th rowspan="1" colspan="1">Sample</th><th rowspan="1" colspan="1">Complex I/CS</th><th rowspan="1" colspan="1">Complex II/CS</th><th rowspan="1" colspan="1">Complex IV/CS</th></tr></thead><tbody align="left"><tr><td rowspan="1" colspan="1">Muscle homogenate</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Control (<italic>n</italic> = 15)</td><td rowspan="1" colspan="1">0.240 &#177; 0.060</td><td rowspan="1" colspan="1">0.320 &#177; 0.088</td><td rowspan="1" colspan="1">1.340 &#177; 0.390</td></tr><tr><td rowspan="1" colspan="1">Patient II-1</td><td rowspan="1" colspan="1">0.053</td><td rowspan="1" colspan="1">0.251</td><td rowspan="1" colspan="1">0.520</td></tr><tr><td rowspan="1" colspan="1">Patient III-10</td><td rowspan="1" colspan="1">0.023</td><td rowspan="1" colspan="1">0.327</td><td rowspan="1" colspan="1">0.244</td></tr><tr><td rowspan="1" colspan="1">Myoblasts</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Control (<italic>n</italic> = 3)</td><td rowspan="1" colspan="1">0.129 &#177; 0.038</td><td rowspan="1" colspan="1">0.262 &#177; 0.067</td><td rowspan="1" colspan="1">0.783 &#177; 0.187</td></tr><tr><td rowspan="1" colspan="1">Patient III-10</td><td rowspan="1" colspan="1">0.089</td><td rowspan="1" colspan="1">0.185</td><td rowspan="1" colspan="1">0.295</td></tr></tbody></table>
###xml 2617 2833 2604 2820 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="45">Sample preparation and enzymatic assays were performed as detailed in Materials and methods section. All respiratory complex activities are ratioed to the activity of the mitochondrial matrix marker citrate synthase.</p>
###xml 2617 2833 2604 2820 <fn xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="45">Sample preparation and enzymatic assays were performed as detailed in Materials and methods section. All respiratory complex activities are ratioed to the activity of the mitochondrial matrix marker citrate synthase.</p></fn>
###xml 2617 2833 2604 2820 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><fn><p textid="45">Sample preparation and enzymatic assays were performed as detailed in Materials and methods section. All respiratory complex activities are ratioed to the activity of the mitochondrial matrix marker citrate synthase.</p></fn></table-wrap-foot>
###xml 2219 2833 2218 2820 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="T1" position="float"><label>Table 1.</label><caption><p textid="44">Biochemical analysis of mitochondrial enzymes from tissue homogenates and myoblasts of patient and control samples</p></caption><table frame="hsides" rules="groups"><thead align="left"><tr><th rowspan="1" colspan="1">Sample</th><th rowspan="1" colspan="1">Complex I/CS</th><th rowspan="1" colspan="1">Complex II/CS</th><th rowspan="1" colspan="1">Complex IV/CS</th></tr></thead><tbody align="left"><tr><td rowspan="1" colspan="1">Muscle homogenate</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Control (<italic>n</italic> = 15)</td><td rowspan="1" colspan="1">0.240 &#177; 0.060</td><td rowspan="1" colspan="1">0.320 &#177; 0.088</td><td rowspan="1" colspan="1">1.340 &#177; 0.390</td></tr><tr><td rowspan="1" colspan="1">Patient II-1</td><td rowspan="1" colspan="1">0.053</td><td rowspan="1" colspan="1">0.251</td><td rowspan="1" colspan="1">0.520</td></tr><tr><td rowspan="1" colspan="1">Patient III-10</td><td rowspan="1" colspan="1">0.023</td><td rowspan="1" colspan="1">0.327</td><td rowspan="1" colspan="1">0.244</td></tr><tr><td rowspan="1" colspan="1">Myoblasts</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">Control (<italic>n</italic> = 3)</td><td rowspan="1" colspan="1">0.129 &#177; 0.038</td><td rowspan="1" colspan="1">0.262 &#177; 0.067</td><td rowspan="1" colspan="1">0.783 &#177; 0.187</td></tr><tr><td rowspan="1" colspan="1">Patient III-10</td><td rowspan="1" colspan="1">0.089</td><td rowspan="1" colspan="1">0.185</td><td rowspan="1" colspan="1">0.295</td></tr></tbody></table><table-wrap-foot><fn><p textid="45">Sample preparation and enzymatic assays were performed as detailed in Materials and methods section. All respiratory complex activities are ratioed to the activity of the mitochondrial matrix marker citrate synthase.</p></fn></table-wrap-foot></table-wrap>
###xml 82 89 <span type="species:ncbi:9606">patient</span>
###xml 367 374 <span type="species:ncbi:9606">patient</span>
###xml 958 965 <span type="species:ncbi:9606">patient</span>
###xml 1324 1332 <span type="species:ncbi:9606">patients</span>
###xml 1800 1807 <span type="species:ncbi:9606">patient</span>
###xml 2314 2321 <span type="species:ncbi:9606">patient</span>
The observation that the very low level of mt-tRNAVal is not recapitulated in the patient-derived cell lines prompted the investigation of mitochondrial protein synthesis and associated functions in the cultured cells. We first assessed the aminoacylation (charged) status of the remaining mt-tRNAVal. RNA was extracted under acidic (pH < 5) conditions from cultured patient (III-10) myoblasts and fractionated through a denaturing polyacrylamide gel. High-resolution northern blots probed for specific mt-tRNAs confirmed the absolute amount of mt-tRNAVal was decreased; however, it also indicated that the proportion of aminoacylated to deacylated mt-tRNAVal was increased [92% (III-10) versus 71% (control) Figure S2]. To determine whether this level of charged mt-tRNAVal was sufficient in these cell lines to allow for normal mitochondrial protein synthesis, the incorporation of 35S-methionine into proteins synthesized in mitochondria was evaluated in patient (III-10) and control myoblasts. Although the 1624C>U mutation disrupts a highly conserved residue and base pairing in the stem of the dihydrouridine (DHU) loop of mt-tRNAVal secondary structure (), there was no marked difference in mitochondrial protein synthesis after either 30 min (data not shown) or 120 min (Figure 2), consistent with the rescue in the patients myoblasts of the profound decrease in complex I activity noted in tissue homogenate (Table 1). Recovery of complex IV activity also occurred, although to a lesser extent. These data show that at least in cultured myoblasts the normal steady-state level of aminoacylated mt-tRNAVal has a weak control strength in mitochondrial protein synthesis. Figure 2.Decreased levels of mt-tRNAVal C25U could not be shown to affect mitochondrial protein synthesis. Myoblasts from patient and control were grown in culture prior to in vivo mitochondrial protein labelling as described in Materials and methods section and (29). Following inhibition of cytosolic protein synthesis, radiolabelled methionine/cysteine was added for 2 h and whole-cell lysates (20 mug total protein) separated by SDS-PAGE. A representative PhosphorImage is shown. Attribution of products is determined by reference to 29.Table 1.Biochemical analysis of mitochondrial enzymes from tissue homogenates and myoblasts of patient and control samplesSampleComplex I/CSComplex II/CSComplex IV/CSMuscle homogenateControl (n = 15)0.240 +/- 0.0600.320 +/- 0.0881.340 +/- 0.390Patient II-10.0530.2510.520Patient III-100.0230.3270.244MyoblastsControl (n = 3)0.129 +/- 0.0380.262 +/- 0.0670.783 +/- 0.187Patient III-100.0890.1850.295Sample preparation and enzymatic assays were performed as detailed in Materials and methods section. All respiratory complex activities are ratioed to the activity of the mitochondrial matrix marker citrate synthase.
###end p 42
###begin p 43
###xml 27 30 27 30 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 165 171 165 171 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n vivo</italic>
###xml 255 257 255 257 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
###xml 113 120 <span type="species:ncbi:9606">patient</span>
Decreased levels of mt-tRNAVal C25U could not be shown to affect mitochondrial protein synthesis. Myoblasts from patient and control were grown in culture prior to in vivo mitochondrial protein labelling as described in Materials and methods section and (29). Following inhibition of cytosolic protein synthesis, radiolabelled methionine/cysteine was added for 2 h and whole-cell lysates (20 mug total protein) separated by SDS-PAGE. A representative PhosphorImage is shown. Attribution of products is determined by reference to 29.
###end p 43
###begin p 44
###xml 87 94 <span type="species:ncbi:9606">patient</span>
Biochemical analysis of mitochondrial enzymes from tissue homogenates and myoblasts of patient and control samples
###end p 44
###begin p 45
Sample preparation and enzymatic assays were performed as detailed in Materials and methods section. All respiratory complex activities are ratioed to the activity of the mitochondrial matrix marker citrate synthase.
###end p 45
###begin title 46
###xml 73 76 73 76 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
The C25U mutation results in increased turnover of the deacylated mt-tRNAVal
###end title 46
###begin p 47
###xml 71 74 71 74 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 176 179 176 179 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 446 449 446 449 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 479 482 479 482 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 484 488 484 488 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MTTV</italic>
###xml 558 561 558 561 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Phe</sup>
###xml 568 572 568 572 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MTTF</italic>
###xml 596 599 596 599 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 609 612 609 612 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Phe</sup>
###xml 652 654 652 654 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 655 657 655 657 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 672 680 672 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">Figure 1</xref>
###xml 811 814 811 814 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 914 917 914 917 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 965 968 965 968 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 1318 1321 1318 1321 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 1333 1341 1333 1341 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Leu(UUR)</sup>
###xml 1379 1387 1379 1387 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F3">Figure 3</xref>
###xml 1470 1473 1470 1473 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 1634 1642 1622 1630 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Leu(UUR)</sup>
###xml 1781 1784 1769 1772 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 2514 2517 2502 2505 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 2642 2645 2630 2633 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 2670 2679 2658 2667 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 3.</label>
###xml 2699 2702 2687 2690 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 2756 2759 2744 2747 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 3032 3035 3020 3023 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 3045 3053 3033 3041 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Leu(UUR)</sup>
###xml 3069 3070 3057 3058 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 3070 3073 3058 3061 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1/2</sub>
###xml 3378 3386 3365 3373 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Leu(UUR)</sup>
###xml 2679 3561 2667 3548 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="48">Stability of mt-tRNA<sup>Val</sup> C25U is impaired. To compare the stability of mt-tRNA<sup>Val</sup> in patients (II-1 and III-10) and control, mitochondrial RNA synthesis was inhibited by the addition of ethidium bromide (250 ng/ml) and the remaining RNA was isolated at the indicated time points. High-resolution blots were then performed with probes specific for mt-tRNA<sup>Val</sup> and &#8211;tRNA<sup>Leu(UUR)</sup>. Estimates for <italic>t</italic><sub>1/2</sub> were calculated by measuring pixel intensity for each mt-tRNA at each time point. For each set of experiments, 5 &#956;g of low molecular weight RNA was separated and equal loading confirmed by reference to the nuclear encoded 5S RNA (data not shown). For ease of comparison, the specific activity of mt-tRNA<sup>Leu(UUR)</sup> probe was decreased to allow both signals to be visualized on the same blot and time course. A representative time course is shown for RNA isolated from the three cell lines.</p>
###xml 2679 3561 2667 3548 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="48">Stability of mt-tRNA<sup>Val</sup> C25U is impaired. To compare the stability of mt-tRNA<sup>Val</sup> in patients (II-1 and III-10) and control, mitochondrial RNA synthesis was inhibited by the addition of ethidium bromide (250 ng/ml) and the remaining RNA was isolated at the indicated time points. High-resolution blots were then performed with probes specific for mt-tRNA<sup>Val</sup> and &#8211;tRNA<sup>Leu(UUR)</sup>. Estimates for <italic>t</italic><sub>1/2</sub> were calculated by measuring pixel intensity for each mt-tRNA at each time point. For each set of experiments, 5 &#956;g of low molecular weight RNA was separated and equal loading confirmed by reference to the nuclear encoded 5S RNA (data not shown). For ease of comparison, the specific activity of mt-tRNA<sup>Leu(UUR)</sup> probe was decreased to allow both signals to be visualized on the same blot and time course. A representative time course is shown for RNA isolated from the three cell lines.</p></caption>
###xml 3561 3561 3548 3548 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn147f3"/>
###xml 2670 3561 2658 3548 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F3" position="float"><label>Figure 3.</label><caption><p textid="48">Stability of mt-tRNA<sup>Val</sup> C25U is impaired. To compare the stability of mt-tRNA<sup>Val</sup> in patients (II-1 and III-10) and control, mitochondrial RNA synthesis was inhibited by the addition of ethidium bromide (250 ng/ml) and the remaining RNA was isolated at the indicated time points. High-resolution blots were then performed with probes specific for mt-tRNA<sup>Val</sup> and &#8211;tRNA<sup>Leu(UUR)</sup>. Estimates for <italic>t</italic><sub>1/2</sub> were calculated by measuring pixel intensity for each mt-tRNA at each time point. For each set of experiments, 5 &#956;g of low molecular weight RNA was separated and equal loading confirmed by reference to the nuclear encoded 5S RNA (data not shown). For ease of comparison, the specific activity of mt-tRNA<sup>Leu(UUR)</sup> probe was decreased to allow both signals to be visualized on the same blot and time course. A representative time course is shown for RNA isolated from the three cell lines.</p></caption><graphic xlink:href="gkn147f3"/></fig>
###xml 142 150 <span type="species:ncbi:9606">patients</span>
###xml 984 991 <span type="species:ncbi:9606">patient</span>
###xml 1133 1140 <span type="species:ncbi:9606">Patient</span>
###xml 1502 1510 <span type="species:ncbi:9606">patients</span>
###xml 1690 1697 <span type="species:ncbi:9606">patient</span>
###xml 1731 1738 <span type="species:ncbi:9606">patient</span>
###xml 2763 2771 <span type="species:ncbi:9606">patients</span>
The 1624C>T mutation led to a decrease in steady-state level of mt-tRNAVal. The decrease was not as profound as in tissue homogenate from the patients and the remaining mt-tRNAVal was sufficient to facilitate normal mitochondrial protein synthesis. However, this variability in levels could be a vital clue to understanding the variable penetrance of this homoplasmic disorder. An investigation was initiated into the lowered steady-state mt-tRNAVal. The mtDNA gene encoding tRNAVal, MTTV is transcribed as part of a polycistronic unit that includes the tRNAPhe gene, MTTF, therefore both mt-tRNAVal and -tRNAPhe are encoded on the same RNA precursor (14,15). As shown in Figure 1 and when compared to other mt-tRNAs encoded on a separate polycistronic unit, it is clear that the decrease is specific to mt-tRNAVal. Thus, the decrease may be due to the mutation causing a more rapid turnover of the mutated mt-tRNAVal. We therefore compared the stability of mt-tRNAVal in control and patient-derived myoblasts following incubation with ethidium bromide, a DNA intercalator that can inhibit transcription of the mitochondrial genome. Patient and control myoblasts were treated with ethidium bromide (250 ng/ml), before harvesting after the indicated time points, RNA was extracted and the steady-state levels of mt-tRNAVal and mt-tRNALeu(UUR) were determined for each time point (Figure 3). Using this concentration of ethidium bromide, the estimated half-life of mt-tRNAVal was considerably reduced in patients III-10 and II-1 (approximately3 h and 3.75 h, respectively), when compared with controls (5.75 h). The half-life of mt-tRNALeu(UUR) did not vary significantly between control and patient II-1 but appears to be longer in patient III-10 (>24 h). Whilst the mutated mt-tRNAVal is clearly being more rapidly degraded, the alteration in calculated half-life (52-65% of control value) was insufficient to explain the substantially reduced steady-state levels (<10% of control value). At steady state, tRNAs are present in both aminoacylated and deacylated forms. To our knowledge, differences in the rates of tRNA decay have never been reported to be dependent on the charged state of the tRNA. However, it is possible that the mutation may cause an alteration in tertiary structure, leading to an increased susceptibility to decay. This may be reduced both by interaction with the cognate synthetase and by aminoacylation. Consequently, one possibility to explain this discrepancy may be that mutated mt-tRNAVal is unstable until aminoacylated. This is supported by the subtle increase in the aminoacylation level of the mutated mt-tRNAVal population (Figure S2). Figure 3.Stability of mt-tRNAVal C25U is impaired. To compare the stability of mt-tRNAVal in patients (II-1 and III-10) and control, mitochondrial RNA synthesis was inhibited by the addition of ethidium bromide (250 ng/ml) and the remaining RNA was isolated at the indicated time points. High-resolution blots were then performed with probes specific for mt-tRNAVal and -tRNALeu(UUR). Estimates for t1/2 were calculated by measuring pixel intensity for each mt-tRNA at each time point. For each set of experiments, 5 mug of low molecular weight RNA was separated and equal loading confirmed by reference to the nuclear encoded 5S RNA (data not shown). For ease of comparison, the specific activity of mt-tRNALeu(UUR) probe was decreased to allow both signals to be visualized on the same blot and time course. A representative time course is shown for RNA isolated from the three cell lines.
###end p 47
###begin p 48
###xml 20 23 20 23 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 77 80 77 80 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 353 356 353 356 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 366 374 366 374 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Leu(UUR)</sup>
###xml 390 391 390 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">t</italic>
###xml 391 394 391 394 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1/2</sub>
###xml 699 707 698 706 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Leu(UUR)</sup>
###xml 84 92 <span type="species:ncbi:9606">patients</span>
Stability of mt-tRNAVal C25U is impaired. To compare the stability of mt-tRNAVal in patients (II-1 and III-10) and control, mitochondrial RNA synthesis was inhibited by the addition of ethidium bromide (250 ng/ml) and the remaining RNA was isolated at the indicated time points. High-resolution blots were then performed with probes specific for mt-tRNAVal and -tRNALeu(UUR). Estimates for t1/2 were calculated by measuring pixel intensity for each mt-tRNA at each time point. For each set of experiments, 5 mug of low molecular weight RNA was separated and equal loading confirmed by reference to the nuclear encoded 5S RNA (data not shown). For ease of comparison, the specific activity of mt-tRNALeu(UUR) probe was decreased to allow both signals to be visualized on the same blot and time course. A representative time course is shown for RNA isolated from the three cell lines.
###end p 48
###begin p 49
###xml 127 129 127 129 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 358 360 358 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B17">17</xref>
###xml 361 363 361 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B18">18</xref>
###xml 520 523 520 523 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 559 567 559 567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 648 651 648 651 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 860 868 860 868 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F4">Figure 4</xref>
###xml 1134 1143 1133 1142 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 4.</label>
###xml 1229 1232 1228 1231 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 1390 1391 1388 1389 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1446 1447 1443 1444 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1570 1573 1567 1570 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 1582 1590 1579 1587 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Leu(UUR)</sup>
###xml 1622 1625 1619 1622 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 1143 1707 1142 1704 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="50">Inhibition of mitochondrial protein synthesis partially restores the levels of mt-tRNA<sup>Val</sup>. Myoblast cell lines from the patient (III-10) and control were treated with 50 &#956;g/ml of the mitochondrial protein synthesis inhibitor thiamphenicol (+TAP, <bold>A</bold>), various concentrations of doxycycline (5 or 10 &#956;M, <bold>B</bold>) or untreated (&#8211;TAP, A or 0, B) and RNA were isolated after 2 days. High-resolution northern blots were probed for mt-tRNA<sup>Val</sup> or &#8211;tRNA<sup>Leu(UUR)</sup> and the relative level of &#8211;tRNA<sup>Val</sup> estimated by normalizing the ratio of the two signals for the untreated controls.</p>
###xml 1143 1707 1142 1704 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="50">Inhibition of mitochondrial protein synthesis partially restores the levels of mt-tRNA<sup>Val</sup>. Myoblast cell lines from the patient (III-10) and control were treated with 50 &#956;g/ml of the mitochondrial protein synthesis inhibitor thiamphenicol (+TAP, <bold>A</bold>), various concentrations of doxycycline (5 or 10 &#956;M, <bold>B</bold>) or untreated (&#8211;TAP, A or 0, B) and RNA were isolated after 2 days. High-resolution northern blots were probed for mt-tRNA<sup>Val</sup> or &#8211;tRNA<sup>Leu(UUR)</sup> and the relative level of &#8211;tRNA<sup>Val</sup> estimated by normalizing the ratio of the two signals for the untreated controls.</p></caption>
###xml 1707 1707 1704 1704 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn147f4"/>
###xml 1134 1707 1133 1704 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F4" position="float"><label>Figure 4.</label><caption><p textid="50">Inhibition of mitochondrial protein synthesis partially restores the levels of mt-tRNA<sup>Val</sup>. Myoblast cell lines from the patient (III-10) and control were treated with 50 &#956;g/ml of the mitochondrial protein synthesis inhibitor thiamphenicol (+TAP, <bold>A</bold>), various concentrations of doxycycline (5 or 10 &#956;M, <bold>B</bold>) or untreated (&#8211;TAP, A or 0, B) and RNA were isolated after 2 days. High-resolution northern blots were probed for mt-tRNA<sup>Val</sup> or &#8211;tRNA<sup>Leu(UUR)</sup> and the relative level of &#8211;tRNA<sup>Val</sup> estimated by normalizing the ratio of the two signals for the untreated controls.</p></caption><graphic xlink:href="gkn147f4"/></fig>
###xml 1263 1270 <span type="species:ncbi:9606">patient</span>
To test this hypothesis, we treated the cells with thiamphenicol, an inhibitor of mitochondrial peptidyl transferase activity (16). As translation elongation is inhibited, aminoacylated mt-tRNAs will be unable to donate their amino acids to the growing peptide, resulting in an increase in the amount of aminoacylated tRNA, as has previously been described (17,18). Thus, by inhibiting mitochondrial protein synthesis there should be an increased level of all aminoacylated tRNAs and consequently an elevation of mt-tRNAVal at steady state. As can be seen in Figure 4A, inhibition with thiamphenicol (TAP) does indeed promote an increase in mt-tRNAVal steady-state levels, but only in the cell line carrying the mutation. To further interrogate this hypothesis, the cells were subjected to a second mitochondrial protein synthesis inhibitor, doxycycline (DOX, Figure 4B), a derivative of tetracycline that inhibits protein synthesis by preventing charged tRNA binding to the A site in the mitoribosome. In agreement with this hypothesis, a graded increase in tRNA levels was noted as the concentration of DOX was increased to 10 muM. Figure 4.Inhibition of mitochondrial protein synthesis partially restores the levels of mt-tRNAVal. Myoblast cell lines from the patient (III-10) and control were treated with 50 mug/ml of the mitochondrial protein synthesis inhibitor thiamphenicol (+TAP, A), various concentrations of doxycycline (5 or 10 muM, B) or untreated (-TAP, A or 0, B) and RNA were isolated after 2 days. High-resolution northern blots were probed for mt-tRNAVal or -tRNALeu(UUR) and the relative level of -tRNAVal estimated by normalizing the ratio of the two signals for the untreated controls.
###end p 49
###begin p 50
###xml 86 89 86 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 247 248 246 247 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 303 304 301 302 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 427 430 425 428 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 439 447 437 445 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Leu(UUR)</sup>
###xml 479 482 477 480 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 120 127 <span type="species:ncbi:9606">patient</span>
Inhibition of mitochondrial protein synthesis partially restores the levels of mt-tRNAVal. Myoblast cell lines from the patient (III-10) and control were treated with 50 mug/ml of the mitochondrial protein synthesis inhibitor thiamphenicol (+TAP, A), various concentrations of doxycycline (5 or 10 muM, B) or untreated (-TAP, A or 0, B) and RNA were isolated after 2 days. High-resolution northern blots were probed for mt-tRNAVal or -tRNALeu(UUR) and the relative level of -tRNAVal estimated by normalizing the ratio of the two signals for the untreated controls.
###end p 50
###begin title 51
###xml 32 37 <span type="species:ncbi:9606">human</span>
Verification that VARS2L is the human mitochondrial valyl-tRNA synthetase
###end title 51
###begin p 52
###xml 41 44 41 44 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 216 219 216 219 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 411 424 411 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S. cerevisiae</italic>
###xml 426 428 426 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B10">10</xref>
###xml 429 431 429 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B11">11</xref>
###xml 1238 1239 1238 1239 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 1245 1253 1245 1253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 1939 1942 1939 1942 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 1957 1965 1957 1965 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 2018 2020 2018 2020 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 2293 2300 2293 2300 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 2321 2326 2321 2326 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20 B21 B22 B23">20&#8211;23</xref>
###xml 2447 2454 2447 2454 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 2459 2462 2459 2462 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 2523 2525 2521 2523 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;3</sup>
###xml 2764 2771 2758 2765 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 2941 2950 2935 2944 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 5.</label>
###xml 2986 2987 2980 2981 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 3211 3212 3205 3206 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 3541 3542 3535 3536 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 3544 3549 3538 3543 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trans</italic>
###xml 2950 4123 2944 4116 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="53">VARS2L is a mitochondrial protein. (<bold>A</bold>) HeLa cells were transiently transfected with a construct expressing the N-terminal 232 residues of VARS2L fused to GFP. Following transfection (24 h), cells were stained with the mitochondriotropic dye Mitotracker Red CM-H<sub>2</sub>XROS. Transfected cells were visualized by fluorescence microscopy. Images were captured and mitochondrial co-localization of the fusion protein was confirmed by superimposition of the green and red signals of a linescan of the image (dashed line visible on image). An image typical of three independent transfections is shown. (<bold>B</bold>) <italic>Trans</italic>mitochondrial HEK293T Flip-in T-REx cybrids inducibly expressing full-length VARS2L were produced as detailed in Materials and methods section. Mitochondrial protein was isolated from control HEK293T Flip-in T-REx cells (293) and the cybrid transfectants (HEK1624 Clone 17) with (+) or without (&#8722;) 48 h of induction as described in the Materials and methods section. Aliquots (100 &#956;g) were subjected to western analysis using anti-VARS2L antibodies. To confirm equal loading of mitochondrial protein, an antibody to mitochondrial ribosome recycling factor (mtRRF) was used.</p>
###xml 2950 4123 2944 4116 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="53">VARS2L is a mitochondrial protein. (<bold>A</bold>) HeLa cells were transiently transfected with a construct expressing the N-terminal 232 residues of VARS2L fused to GFP. Following transfection (24 h), cells were stained with the mitochondriotropic dye Mitotracker Red CM-H<sub>2</sub>XROS. Transfected cells were visualized by fluorescence microscopy. Images were captured and mitochondrial co-localization of the fusion protein was confirmed by superimposition of the green and red signals of a linescan of the image (dashed line visible on image). An image typical of three independent transfections is shown. (<bold>B</bold>) <italic>Trans</italic>mitochondrial HEK293T Flip-in T-REx cybrids inducibly expressing full-length VARS2L were produced as detailed in Materials and methods section. Mitochondrial protein was isolated from control HEK293T Flip-in T-REx cells (293) and the cybrid transfectants (HEK1624 Clone 17) with (+) or without (&#8722;) 48 h of induction as described in the Materials and methods section. Aliquots (100 &#956;g) were subjected to western analysis using anti-VARS2L antibodies. To confirm equal loading of mitochondrial protein, an antibody to mitochondrial ribosome recycling factor (mtRRF) was used.</p></caption>
###xml 4123 4123 4116 4116 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn147f5"/>
###xml 2941 4123 2935 4116 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F5" position="float"><label>Figure 5.</label><caption><p textid="53">VARS2L is a mitochondrial protein. (<bold>A</bold>) HeLa cells were transiently transfected with a construct expressing the N-terminal 232 residues of VARS2L fused to GFP. Following transfection (24 h), cells were stained with the mitochondriotropic dye Mitotracker Red CM-H<sub>2</sub>XROS. Transfected cells were visualized by fluorescence microscopy. Images were captured and mitochondrial co-localization of the fusion protein was confirmed by superimposition of the green and red signals of a linescan of the image (dashed line visible on image). An image typical of three independent transfections is shown. (<bold>B</bold>) <italic>Trans</italic>mitochondrial HEK293T Flip-in T-REx cybrids inducibly expressing full-length VARS2L were produced as detailed in Materials and methods section. Mitochondrial protein was isolated from control HEK293T Flip-in T-REx cells (293) and the cybrid transfectants (HEK1624 Clone 17) with (+) or without (&#8722;) 48 h of induction as described in the Materials and methods section. Aliquots (100 &#956;g) were subjected to western analysis using anti-VARS2L antibodies. To confirm equal loading of mitochondrial protein, an antibody to mitochondrial ribosome recycling factor (mtRRF) was used.</p></caption><graphic xlink:href="gkn147f5"/></fig>
###xml 405 410 <span type="species:ncbi:4932">yeast</span>
###xml 411 424 <span type="species:ncbi:4932">S. cerevisiae</span>
###xml 1926 1931 <span type="species:ncbi:9606">human</span>
###xml 2293 2300 <span type="species:ncbi:562">E. coli</span>
###xml 2447 2454 <span type="species:ncbi:562">E. coli</span>
###xml 2764 2771 <span type="species:ncbi:562">E. coli</span>
If the deacylated form of mutated mt-tRNAVal is indeed more susceptible to degradation than either its aminoacylated form or its wild-type counterpart, it may be possible to increase the steady-state level of mt-tRNAVal by increasing aminoacylation activity. As already described in the Introduction section, over-expression of cognate synthetases has been shown to rescue various mutated mt-tRNAs in the yeast S. cerevisiae (10,11). Although appealing, this approach was complicated at the outset of these experiments by the absence of any reported mitochondrial valyl synthetase. A simple bioinformatic search revealed a strong candidate protein (KIAA1885/VARS2L) containing the HIGH and KMSKS signature motifs of the class I aminoacyl synthetases. The original UNIPROT/TrEMBL entry (Q96QO2) failed to identify an N-terminal methionine but a facile search revealed a candidate methionine 36 residues within the sequence. Strong mitochondrial import predictions were made from MitoProt () and TargetP (), 82.2 and 87.9%, respectively. To confirm mitochondrial localization, a C-terminal GFP fusion construct was produced and transient transfection revealed good co-localization with the mitochondrial-specific marker Mitotracker Red CM-H2XRos (Figure 5A). To purify the protein and determine the aminoacylation activity of VARS2L, various fusion constructs were made each with a short, predicted N-terminal pre-sequence deletion. In all cases irrespective of the background strain or conditions of expression, only aggregated VARS2L could be made (data not shown). To resolve these problems with aggregation, more extensive N-terminal truncations of VARS2L fused to GST were designed, ensuring that all predicted functional domains were retained in the protein. All constructs were expressed and soluble VARS2L purified following removal of GST as described in Materials and methods section (Figure S3). As initial template, human mt-tRNAVal was generated in vitro following the ribozyme method outlined in  and ref. 19. Unfortunately, only minimal aminoacylation activity above background activity could be detected using tRNA produced from several independent assays (data not shown). The majority of previous reports detailing the function of mammalian mitochondrial synthetases have used E. coli tRNA as substrates (20-23). Using the soluble VARS2L carrying a 102 residue N-terminal deletion, tritiated valine was successfully transferred to E. coli tRNAVal, albeit with a low aminoacylation activity (1.2 +/- 0.2 x 10-3 pmol aminoacylated tRNA/min/pmol for VARS2LDelta102, ). Similarly, low-level activity was noted for all other N-terminal deletions (data not shown). To confirm the activity was indeed due to VARS2L and not to any remnant of contaminating E. coli protein, activity was also noted with enzyme immunoprecipitated from the reaction mix with the anti-VARS2L antibodies prior to initiation of the assay (data not shown). Figure 5.VARS2L is a mitochondrial protein. (A) HeLa cells were transiently transfected with a construct expressing the N-terminal 232 residues of VARS2L fused to GFP. Following transfection (24 h), cells were stained with the mitochondriotropic dye Mitotracker Red CM-H2XROS. Transfected cells were visualized by fluorescence microscopy. Images were captured and mitochondrial co-localization of the fusion protein was confirmed by superimposition of the green and red signals of a linescan of the image (dashed line visible on image). An image typical of three independent transfections is shown. (B) Transmitochondrial HEK293T Flip-in T-REx cybrids inducibly expressing full-length VARS2L were produced as detailed in Materials and methods section. Mitochondrial protein was isolated from control HEK293T Flip-in T-REx cells (293) and the cybrid transfectants (HEK1624 Clone 17) with (+) or without (-) 48 h of induction as described in the Materials and methods section. Aliquots (100 mug) were subjected to western analysis using anti-VARS2L antibodies. To confirm equal loading of mitochondrial protein, an antibody to mitochondrial ribosome recycling factor (mtRRF) was used.
###end p 52
###begin p 53
###xml 36 37 36 37 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 261 262 261 262 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sub>
###xml 591 592 591 592 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 594 599 594 599 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Trans</italic>
VARS2L is a mitochondrial protein. (A) HeLa cells were transiently transfected with a construct expressing the N-terminal 232 residues of VARS2L fused to GFP. Following transfection (24 h), cells were stained with the mitochondriotropic dye Mitotracker Red CM-H2XROS. Transfected cells were visualized by fluorescence microscopy. Images were captured and mitochondrial co-localization of the fusion protein was confirmed by superimposition of the green and red signals of a linescan of the image (dashed line visible on image). An image typical of three independent transfections is shown. (B) Transmitochondrial HEK293T Flip-in T-REx cybrids inducibly expressing full-length VARS2L were produced as detailed in Materials and methods section. Mitochondrial protein was isolated from control HEK293T Flip-in T-REx cells (293) and the cybrid transfectants (HEK1624 Clone 17) with (+) or without (-) 48 h of induction as described in the Materials and methods section. Aliquots (100 mug) were subjected to western analysis using anti-VARS2L antibodies. To confirm equal loading of mitochondrial protein, an antibody to mitochondrial ribosome recycling factor (mtRRF) was used.
###end p 53
###begin title 54
###xml 79 82 79 82 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 88 89 88 89 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&gt;</bold>
Induction of VARS2L results in increased steady-state levels of cognate mt-tRNAVal 1624C>T
###end title 54
###begin p 55
###xml 13 14 11 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sup>
###xml 58 63 56 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 365 368 363 366 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 514 515 510 511 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">0</sup>
###xml 1724 1732 1720 1728 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F5">Figure 5</xref>
###xml 595 600 <span type="species:ncbi:9606">human</span>
###xml 1030 1037 <span type="species:ncbi:9606">patient</span>
Recipient rho0 cell lines that have been used to generate transmitochondrial cybrids are notoriously aneuploid and data produced by uncontrolled over-expression of exogenous proteins in individual clones has to be interpreted with great caution. Consequently, to show unequivocally that over-expression of the synthetase could increase aminoacylation of the mt-tRNAVal and restore steady-state levels, it was necessary to control expression of the synthetase in any cybrid. To date, such an inducible recipient rho0 cell line is not available. To tackle this problem, the commercially available human cell line with a defined integration site that allows inducible expression (HEK293 Flip-In T-REx) was subjected to long-term culture in low-dose ethidium bromide to deplete cells of endogenous mtDNA. Complete removal of mtDNA was found not to be possible, although copy number was depleted to <1% of untreated controls (data not shown). Cybrids were generated by fusion of these mtDNA-depleted cells with cytoplasts derived from patient fibroblasts and selected as detailed in Materials and methods section. DNA was isolated from the cybrids and following RFLP analysis, three clones (clone 5, 11 and 17) containing >94% levels of 1624C>T were retained. Similar to the cell lines homoplasmic for the mutation, biochemical analysis of clone 17 revealed no profound respiratory defect (data not shown). These three cell lines were transfected with the full-length VARS2L-encoding cDNA and stable, tetracycline inducible cell lines were selected as detailed. To confirm expression, transfectants were expanded, induced and mitochondrial extracts subjected to western analysis with anti-VARS2L specific antibodies. As shown in Figure 5B, although the endogenous levels of VARS2L were only just detectable, even in large amounts of mitochondrial protein (100 mug, lane a), good induction was noted for each clone.
###end p 55
###begin p 56
###xml 188 191 188 191 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 322 330 322 330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 415 418 415 418 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 538 546 538 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 596 599 584 587 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 877 880 865 868 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 1247 1250 1234 1237 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 1373 1381 1360 1368 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F6">Figure 6</xref>
###xml 1505 1508 1492 1495 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 1547 1556 1534 1543 <label xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure 6.</label>
###xml 1642 1645 1629 1632 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 1648 1649 1635 1636 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 1842 1845 1829 1832 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 1855 1863 1842 1850 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Leu(UUR)</sup>
###xml 2068 2071 2055 2058 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 2080 2088 2067 2075 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Leu(UUR)</sup>
###xml 2113 2114 2100 2101 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 1556 2430 1543 2417 <p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" textid="57">Over-expression of human VARS2L can increase the steady-state level of mutated mt-tRNA<sup>Val</sup>. (<bold>A</bold>) HEK293T1624C&gt;T clone 17 transfected cybrids, uninduced (&#8722;) or induced (+) were grown for 3 days prior to isolation of RNA. High-resolution northern blots were performed with probes to mt-tRNA<sup>Val</sup> and &#8211;tRNA<sup>Leu(UUR)</sup> as indicated. Natural levels for both tRNA species are shown in the control untransfected HEK293 cell line (293). Signal was quantified by ImageQuant after PhosphorImager exposure and the ratio of mt-tRNA<sup>Val</sup> to &#8211;tRNA<sup>Leu(UUR)</sup> given for each sample. (<bold>B</bold>) Extended over-expression of VARS2L maintains the increased steady-state level of mutated mt-tRNAVal. A similar experiment to (A) was performed, with RNA isolated after the indicated induction time in days. Ratios of the mt-tRNAs are shown for control untreated (293) and the 143B1624C&gt;T homoplasmic cybrids (143B).</p>
###xml 1556 2430 1543 2417 <caption xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><p textid="57">Over-expression of human VARS2L can increase the steady-state level of mutated mt-tRNA<sup>Val</sup>. (<bold>A</bold>) HEK293T1624C&gt;T clone 17 transfected cybrids, uninduced (&#8722;) or induced (+) were grown for 3 days prior to isolation of RNA. High-resolution northern blots were performed with probes to mt-tRNA<sup>Val</sup> and &#8211;tRNA<sup>Leu(UUR)</sup> as indicated. Natural levels for both tRNA species are shown in the control untransfected HEK293 cell line (293). Signal was quantified by ImageQuant after PhosphorImager exposure and the ratio of mt-tRNA<sup>Val</sup> to &#8211;tRNA<sup>Leu(UUR)</sup> given for each sample. (<bold>B</bold>) Extended over-expression of VARS2L maintains the increased steady-state level of mutated mt-tRNAVal. A similar experiment to (A) was performed, with RNA isolated after the indicated induction time in days. Ratios of the mt-tRNAs are shown for control untreated (293) and the 143B1624C&gt;T homoplasmic cybrids (143B).</p></caption>
###xml 2430 2430 2417 2417 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xlink:href="gkn147f6"/>
###xml 1547 2430 1534 2417 <fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="F6" position="float"><label>Figure 6.</label><caption><p textid="57">Over-expression of human VARS2L can increase the steady-state level of mutated mt-tRNA<sup>Val</sup>. (<bold>A</bold>) HEK293T1624C&gt;T clone 17 transfected cybrids, uninduced (&#8722;) or induced (+) were grown for 3 days prior to isolation of RNA. High-resolution northern blots were performed with probes to mt-tRNA<sup>Val</sup> and &#8211;tRNA<sup>Leu(UUR)</sup> as indicated. Natural levels for both tRNA species are shown in the control untransfected HEK293 cell line (293). Signal was quantified by ImageQuant after PhosphorImager exposure and the ratio of mt-tRNA<sup>Val</sup> to &#8211;tRNA<sup>Leu(UUR)</sup> given for each sample. (<bold>B</bold>) Extended over-expression of VARS2L maintains the increased steady-state level of mutated mt-tRNAVal. A similar experiment to (A) was performed, with RNA isolated after the indicated induction time in days. Ratios of the mt-tRNAs are shown for control untreated (293) and the 143B1624C&gt;T homoplasmic cybrids (143B).</p></caption><graphic xlink:href="gkn147f6"/></fig>
###xml 1575 1580 <span type="species:ncbi:9606">human</span>
Following confirmation of transfection, clone 17 was expanded. The high level of heteroplasmy for the 1624C>T mutation was retained. Further, the steady-state level of mutated C25U mt-tRNAVal was confirmed to be lower than the wild type in HEK293 Flip-In T-REx control cells as measured by high-resolution northern blots (Figure 6). To determine whether the over-expression of VARS2L could promote increased mt-tRNAVal, cells were initially induced for 3 days prior to harvesting, RNA isolation and analysis by northern blot. As shown in Figure 6A, approximately4-fold increase in mutated mt-tRNAVal was apparent, increasing levels to almost 50% of the control HEK293 Flip-In T-REx line carrying wild-type mtDNA. The control fusion of HEK293/1624C>T that carried the mutation but were untransfected and so could not express the cognate synthetase, showed no increase in mt-tRNAVal levels under identical induction conditions (Figure S4), consistent with growth of HEK293 Flip-In T-REx cells in 1 mug/ml inducer for up to 2 weeks having no measurable effect on the rates of mitochondrial protein synthesis (data not shown). Further, over-expression of VARS2L in cybrid clones retaining the 1624C genotype resulted in no apparent increase of mt-tRNAVal steady-state levels (Figure S5). A more detailed time course also confirmed an increase at 3, 5 and 7 day post-induction (Figure 6B), consistent with the over-expression of the mitochondrial valyl synthetase partially suppressing the depletion of mt-tRNAVal associated with the 1624C>T mutation. Figure 6.Over-expression of human VARS2L can increase the steady-state level of mutated mt-tRNAVal. (A) HEK293T1624C>T clone 17 transfected cybrids, uninduced (-) or induced (+) were grown for 3 days prior to isolation of RNA. High-resolution northern blots were performed with probes to mt-tRNAVal and -tRNALeu(UUR) as indicated. Natural levels for both tRNA species are shown in the control untransfected HEK293 cell line (293). Signal was quantified by ImageQuant after PhosphorImager exposure and the ratio of mt-tRNAVal to -tRNALeu(UUR) given for each sample. (B) Extended over-expression of VARS2L maintains the increased steady-state level of mutated mt-tRNAVal. A similar experiment to (A) was performed, with RNA isolated after the indicated induction time in days. Ratios of the mt-tRNAs are shown for control untreated (293) and the 143B1624C>T homoplasmic cybrids (143B).
###end p 56
###begin p 57
###xml 86 89 86 89 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 92 93 92 93 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">A</bold>
###xml 286 289 286 289 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 299 307 299 307 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Leu(UUR)</sup>
###xml 512 515 512 515 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 524 532 524 532 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Leu(UUR)</sup>
###xml 557 558 557 558 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B</bold>
###xml 19 24 <span type="species:ncbi:9606">human</span>
Over-expression of human VARS2L can increase the steady-state level of mutated mt-tRNAVal. (A) HEK293T1624C>T clone 17 transfected cybrids, uninduced (-) or induced (+) were grown for 3 days prior to isolation of RNA. High-resolution northern blots were performed with probes to mt-tRNAVal and -tRNALeu(UUR) as indicated. Natural levels for both tRNA species are shown in the control untransfected HEK293 cell line (293). Signal was quantified by ImageQuant after PhosphorImager exposure and the ratio of mt-tRNAVal to -tRNALeu(UUR) given for each sample. (B) Extended over-expression of VARS2L maintains the increased steady-state level of mutated mt-tRNAVal. A similar experiment to (A) was performed, with RNA isolated after the indicated induction time in days. Ratios of the mt-tRNAs are shown for control untreated (293) and the 143B1624C>T homoplasmic cybrids (143B).
###end p 57
###begin title 58
DISCUSSION
###end title 58
###begin p 59
###xml 75 78 75 78 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 308 315 308 315 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 407 410 407 410 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 646 648 646 648 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 1017 1026 1017 1026 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">bona fide</italic>
###xml 1244 1251 1244 1251 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E. coli</italic>
###xml 1388 1396 1388 1396 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1422 1425 1422 1425 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 1587 1589 1587 1589 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
###xml 1590 1592 1590 1592 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 1593 1595 1593 1595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 1709 1717 1709 1717 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 1759 1764 1759 1764 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20 B21 B22 B23">20&#8211;23</xref>
###xml 1964 1966 1964 1966 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 1967 1969 1967 1969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 2045 2048 2045 2048 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 2151 2154 2151 2154 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 205 210 <span type="species:ncbi:9606">human</span>
###xml 308 315 <span type="species:ncbi:562">E. coli</span>
###xml 721 726 <span type="species:ncbi:9606">human</span>
###xml 1244 1251 <span type="species:ncbi:562">E. coli</span>
###xml 1409 1414 <span type="species:ncbi:9606">human</span>
In this report, we show data that is consistent with the pathogenic mt-tRNAVal mutation causing a defect in stability, which is partially protected by charging of the mt-tRNA. We confirm the identity of a human mitochondrial valyl synthetase, VARS2L, that we show is localized to mitochondria and can charge E. coli tRNA with valine. Finally, we show that the depleted steady-state level of the C25U mt-tRNAVal can be partially recovered by over-expression of the cognate mitochondrial synthetase. At the onset of these studies, there had been no report of any candidate mitochondrial valyl synthetase. However, in 2005, Florentz and colleagues (20) reported a list of candidates for the remainder of the uncharacterized human mitochondrial synthetases, which they identified by database mining. This included reference to a different form of VARS2L. Amongst the aims of this current research, we wished to demonstrate and confirm mitochondrial localization of our version of VARS2L and to determine whether it was a bona fide mitochondrial valyl synthetase, not to complete a full biochemical characterization of this protein. Indeed, our initial studies confirmed co-localization and valyl synthetase activity of this enzyme when using total E. coli tRNA as substrate, albeit with very low specific activity. We were unable to show any great efficiency of aminoacylation by VARS2L with in vitro transcribed human mt-tRNAVal as substrate. However, it has been well documented that mammalian mitochondrial synthetases are less efficient than their cytosolic or prokaryotic counterparts (21,22,24). Further, full optimization of conditions had not been performed for this enzyme. Lower activity with mammalian in vitro transcribed mt-tRNA is also not unusual (20-23). There are clearly cases where post-transcriptional modifications are essential for robust aminoacylation and in the absence of correct modifications tRNAs have been shown occasionally to mis-fold (25,26). Although not unexpected, the poor aminoacylation of the synthetic mt-tRNAVal meant it was not possible to compare the aminoacylation efficiencies of the wild-type and mutated tRNAVal substrates.
###end p 59
###begin p 60
###xml 82 85 82 85 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 162 167 162 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 319 322 319 322 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 563 566 563 566 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 769 771 769 771 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 772 774 772 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 847 850 847 850 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 889 892 889 892 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 1206 1209 1206 1209 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
###xml 1435 1440 1435 1440 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">trans</italic>
###xml 1719 1722 1719 1722 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
We conclude that it is the rapid decay rate of the deacylated form of C25U mt-tRNAVal, which is responsible for its low steady-state level in all the primary and transmitochondrial cybrid cell lines that we have generated and studied. This conclusion is based on the following criteria: (i) shorter half-life of mt-tRNAVal was observed following inhibition of mitochondrial transcription, (ii) inhibition of mitochondrial protein synthesis, a condition likely to increase aminoacylation states of all mt-tRNAs, led to increased steady-state levels of C25U mt-tRNAVal, (iii) the G10-C25 pairing in the D-stem of tRNAs has been implicated in contacting the cognate class I synthetases, suggesting mutations in this pairing may result in decreased association/protection (27,28) and (iv) over-expression of VARS2L promoted an increase in C25U mt-tRNAVal levels. Partial restoration of mt-tRNAVal levels by over-expression of VARS2L was impressive but as no cell line containing the 1624C>T substitution showed a profound defect in biochemical activity of any mitochondrial respiratory enzyme, we have limited this study to understanding the mechanisms underlying the decreased stability of the mutated mt-tRNAVal. However, with reference to this difficulty in recapitulating respiratory defects due to the 1624C>T mutation, it is interesting to note that we are currently characterizing several independent 143B-based homoplasmic 1624C>T transmitochondrial cybrid clones that are unable to grow on galactose, consistent with these clones being compromised for OXPHOS. This defect is due to the aneuploid nature of the cybrids and amongst several possibilities, may be caused by differing steady-state levels of the mt-tRNAVal.
###end p 60
###begin p 61
###xml 69 73 69 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MTTV</italic>
###xml 546 549 546 549 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
We have previously reported that this unique homoplasmic mutation in MTTV underlies a multi-system disease affecting three generations of a family. Despite its homoplasmic nature, this mutation has an extremely diverse clinical phenotype with at least one individual remaining only mildly affected. This diversity is not reflected in the biochemical deficiency in muscle as in the profound (III-10) and mildly affected (II-10) individuals, both showed severe defects in respiratory complex activities. However, there may be variability in mt-tRNAVal levels in neuronal or cardiac tissue, which may cause differences in mitochondrial protein synthesis and consequently respiratory complex defects.
###end p 61
###begin p 62
###xml 139 143 139 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MTTV</italic>
###xml 869 872 869 872 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Val</sup>
In summary, on the basis of the data provided in this article, we propose the following hypothesis for the variable effects of the 1624C>T MTTV mutation. Steady-state levels are a result of the rate of tRNA production (synthesis, processing, maturation) minus the rate of decay. This mutation causes an increased decay rate of the deacylated form, which is offset in part by aminoacylation. We predict that the dramatic differences in steady-state levels is due to natural variabilities in the rates of synthesis and decay of the deacylated mutant form in a given cell type and the relative amounts of valyl synthetase available to promote increased aminoacylation and therefore increased stability. This hypothesis predicts that although these rates will vary between tissues, over-expression of VARS2L within a tissue will always increase the level of charged mt-tRNAVal steady-state levels, potentially restoring mitochondrial protein synthesis. Testing this hypothesis may lead to a greater understanding of the pathophysiology of mitochondrial disease and to formulating novel therapeutic approaches for these devastating disorders.
###end p 62
###begin title 63
SUPPLEMENTARY DATA
###end title 63
###begin p 64
 are available at NAR Online.
###end p 64
###begin title 65
Supplementary Material
###end title 65
###begin title 66
[Supplementary Data]
###end title 66
###begin title 67
ACKNOWLEDGEMENTS
###end title 67
###begin p 68
R.N.L., Z.M.A.C.L, R.W.T. and D.M.T. wish to thank the Wellcome Trust for supporting this work. R.M. is funded by a Fellowship from the Medical Research Council, J.R. by an MCEST Fellowship from the EU (Contract MEST-CT-FP6-503684) and A.Y. and D.A.K. by the Malaysian Government. We gratefully acknowledge assistance with respiratory chain (LangPing He) and aminoacylation assays (Andre Dietrich and Anne Cosset, IBMP Strasbourg). Funding to pay the Open Access publication charges for this article was provided by The Wellcome Trust.
###end p 68
###begin p 69
###xml 0 30 0 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Conflict of interest statement</italic>
Conflict of interest statement. None declared.
###end p 69
###begin title 70
REFERENCES
###end title 70
###begin article-title 71
###xml 31 36 <span type="species:ncbi:9606">human</span>
Mitochondrial DNA mutations in human disease
###end article-title 71
###begin article-title 72
Mitochondrial disorders
###end article-title 72
###begin article-title 73
Mitochondrial DNA mutation associated with Leber's hereditary optic neuropathy
###end article-title 73
###begin article-title 74
Pathogenic expression of homoplasmic mtDNA mutations needs a complex nuclear-mitochondrial interaction
###end article-title 74
###begin article-title 75
Mitochondrial ribosomal RNA mutation associated with both antibiotic-induced and non-syndromic deafness
###end article-title 75
###begin article-title 76
Variable penetrance of a familial progressive necrotising encephalopathy due to a novel tRNA(Ile) homoplasmic mutation in the mitochondrial genome
###end article-title 76
###begin article-title 77
Homoplasmy, heteroplasmy, and mitochondrial dystonia
###end article-title 77
###begin article-title 78
Multiple neonatal deaths due to a homoplasmic mitochondrial DNA mutation
###end article-title 78
###begin article-title 79
A homoplasmic mitochondrial transfer ribonucleic acid mutation as a cause of maternally inherited hypertrophic cardiomyopathy
###end article-title 79
###begin article-title 80
A missense mutation in the nuclear gene coding for the mitochondrial aspartyl-tRNA synthetase suppresses a mitochondrial tRNA(Asp) mutation
###end article-title 80
###begin article-title 81
###xml 13 18 <span type="species:ncbi:4932">yeast</span>
Mutations in yeast mt tRNAs: specific and general suppression by nuclear encoded tRNA interactors
###end article-title 81
###begin article-title 82
###xml 42 47 <span type="species:ncbi:9606">human</span>
Reversal of a mitochondrial DNA defect in human skeletal muscle
###end article-title 82
###begin article-title 83
###xml 33 38 <span type="species:ncbi:10090">mouse</span>
Production of transmitochondrial mouse cell lines by cybrid rescue of rhodamine-6G pre-treated L-cells
###end article-title 83
###begin article-title 84
Post-transcriptional regulation of the steady-state levels of mitochondrisl tRNAs in HeLa cells
###end article-title 84
###begin article-title 85
###xml 36 41 <span type="species:ncbi:9606">human</span>
The pattern of transcription of the human mitochondrial rRNA genes reveals two overlapping transcription units
###end article-title 85
###begin article-title 86
The interference of chloramphenicol and thiamphenicol with the biogenesis of mitochondria in animal tissues. A possible clue to the toxic action
###end article-title 86
###begin article-title 87
A novel role for aminoacyl-tRNA synthetases in the regulation of polypeptide chain initiation
###end article-title 87
###begin article-title 88
Effect of extreme amino acid starvation on the protein synthetic machinery of CHO cells
###end article-title 88
###begin article-title 89
A one-step method for in vitro production of tRNA transcripts
###end article-title 89
###begin article-title 90
###xml 23 28 <span type="species:ncbi:9606">human</span>
Toward the full set of human mitochondrial aminoacyl-tRNA synthetases: characterization of AspRS and TyrRS
###end article-title 90
###begin article-title 91
###xml 37 42 <span type="species:ncbi:9606">human</span>
Expression and characterization of a human mitochondrial phenylalanyl-tRNA synthetase
###end article-title 91
###begin article-title 92
###xml 39 44 <span type="species:ncbi:9606">human</span>
Expression and characterization of the human mitochondrial leucyl-tRNA synthetase
###end article-title 92
###begin article-title 93
###xml 24 29 <span type="species:ncbi:9606">human</span>
Characterization of the human mitochondrial methionyl-tRNA synthetase
###end article-title 93
###begin article-title 94
###xml 39 44 <span type="species:ncbi:9606">human</span>
Identification and characterization of human mitochondrial tryptophanyl-tRNA synthetase
###end article-title 94
###begin article-title 95
###xml 77 82 <span type="species:ncbi:9606">human</span>
The presence of modified nucleotides is required for cloverleaf folding of a human mitochondrial tRNA
###end article-title 95
###begin article-title 96
###xml 15 20 <span type="species:ncbi:9606">human</span>
Recognition of human mitochondrial tRNALeu(UUR) by its cognate leucyl-tRNA synthetase
###end article-title 96
###begin article-title 97
###xml 13 20 <span type="species:ncbi:562">E. coli</span>
Structure of E. coli glutaminyl-tRNA synthetase complexed with tRNA(Gln) and ATP at 2.8 A resolution
###end article-title 97
###begin article-title 98
###xml 31 51 <span type="species:ncbi:274">Thermus thermophilus</span>
The 2.0 A crystal structure of Thermus thermophilus methionyl-tRNA synthetase reveals two RNA-binding modules
###end article-title 98
###begin article-title 99
###xml 33 38 <span type="species:ncbi:9606">human</span>
In vivo labeling and analysis of human mitochondrial translation products
###end article-title 99

